Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
407,379

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Zacks Equity Research

Abbott (ABT) to Upgrade PHCs Across India With New Pact

by Zacks Equity Research

Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.

Zacks Equity Research

Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues

by Zacks Equity Research

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

Zacks Equity Research

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

SmileDirectClub (SDC) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives for SmileDirectClub (SDC).

Zacks Equity Research

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) continued strength across its certain end markets.

Zacks Equity Research

Here's Why You Should Retain Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.

Zacks Equity Research

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

Zacks Equity Research

McKesson (MCK) Announces Availability of FDA-Accepted Drug

by Zacks Equity Research

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.

Zacks Equity Research

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Zacks Equity Research

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

Zacks Equity Research

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strong growth in the base business.

Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 3 integration with mylife Loop solutions will help build a smart, automated process to deliver insulin based on real-time glucose data.

Zacks Equity Research

Walgreens Boots (WBA) Gains From Digital Sales Amid Cost Woes

by Zacks Equity Research

Within the U.S. Healthcare segment, Walgreens Boots (WBA) is optimistic about the acquisition of CareCentrix.

Zacks Equity Research

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.

Zacks Equity Research

Thermo Fisher's (TMO) Monkeypox Test Receives FDA EUA

by Zacks Equity Research

Thermo Fisher's (TMO) monkeypox test kit is a PCR test intended to spot non-variola Orthopoxviruses, including the monkeypox virus.

Zacks Equity Research

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Zacks Equity Research

McKesson (MCK) Announces Availability of FDA-Approved Drug

by Zacks Equity Research

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.

Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.

Zacks Equity Research

Abbott's (ABT) Eterna SCS System Receives FDA's Approval

by Zacks Equity Research

Abbott's (ABT) Eterna SCS technology shows 23% more pain reduction compared with traditional waveform technology approaches.